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A B S T R A C T   
Mucolipidosis type II (MLII, MIM 252500) is a lysosomal storage disorders caused by defects in GNPTAB gene 
which encodes alpha and beta subunits of N-acetylglucosamine (GlcNAc)-1-phosphotransferase. Neonatal pre-
sentation includes coarse facial features, restricted postnatal growth, generalized hypotonia, gingival hyper-
trophy and multiple skeletal anomalies. Here we present a case of a 26-week gestational age preterm infant with 
MLII who did not exhibit the typical facial features at birth; however, the diagnosis was suggested from abnormal 
placental pathology showing trophoblastic lipidosis and initial skeletal abnormalities from chest radiograph 
revealing generalized diffuse severe bone demineralizing disease and multiple fractures. Biochemical testing 
revealed elevation of plasma lysosomal enzymes. Homozygous pathogenic variant, designated c.3505_3504del, 
was discovered from GNPTAB sequencing. Her course was complicated by respiratory distress, secondary hy-
perparathyroidism, abdominal distention and feeding difficulties. Urine mucopolysaccharides analysis revealed 
mild elevation of total and individual glycosaminoglycan species in a non-specific pattern. To our knowledge, our 
case is the most premature example of mucolipidosis type II that has ever been reported to date. This report 
highlights the importance of placental pathological studies in the diagnosis of lysosomal storage disorders.   
1. Introduction 
Mucolipidosis type II (MLII, also known as I-cell disease), along with 
mucolipidosis type III alpha/beta (MLIIIα/β) and mucolipidosis type III 
gamma (MLIIIγ), are lysosomal storage disorders caused by defects in N- 
acetylglucosamine (GlcNAc)-1-phosphotransferase [1,2]. GlcNAc-1- 
phosphotransferase is a hexameric enzyme composed of 2 alpha, 2 
beta and 2 gamma subunits [2,3]. GNPTAB encodes the alpha and beta 
subunits, while GNPTG encodes the gamma subunit [4,5]. This enzyme 
catalyzes the phosphorylation of mannose residues on glycan chains to 
form mannose-6-phosphate, which is required for targeting lysosomal 
enzymes to lysosomes [6]. The defect of GlcNAc-1-phosphotransferase 
causes hypersecretion of lysosomal enzymes leading to the elevation 
of multiple acid hydrolase activities in the serum and their deficiency in 
the lysosomes. [7]. The subsequent accumulation of intracellular ma-
terials results in cellular dysfunction and eventually tissue and organ 
damage [8]. 
GNPTAB is located at chromosome 12q23.2 and contains 21 exons. 
Pathogenic variants in GNPTAB cause MLII (MIM 252500) and MLIIIα/β 
(МІM 252600) [2,9]. MLII is characterized by neonatal onset of coarse 
facial features, restricted postnatal growth, generalized hypotonia, 
gingival hypertrophy and multiple skeletal abnormalities including 
thoracic deformity, clubfeet, long bone deformity, hip dislocation, and 
cardiac valvular abnormalities [1,10–14]. MLIIIα/β is a later-onset form 
which is typically diagnosed around three years of age and has slower 
progression [1,10–14]. Those with MLIIIα/β typically live into early 
adulthood, while most patients with MLII die in early childhood, usually 
with respiratory compromise [15]. Genotype-phenotype correlation has 
been established in MLII and MLIIIα/β. Variants that severely affect 
enzyme function have been shown to be associated with more severe 
phenotypes [1,16]. 
Previous studies have reported abnormal placental lipid 
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accumulation in newborns with mucolipidoses and other lysosomal 
storage diseases [17–19]. We present the case of a premature newborn 
with MLII who at birth did not exhibit any of the typical dysmorphic 
features including those of the facies. It was on the basis of the placental 
examination and radiographic findings of the chest that the diagnosis of 
I-cell disease was suspected and subsequently corroborated through 
biochemical and genetic testing. 
2. Materials and methods 
2.1. Case report 
The patient was a 3-day-old female who was admitted to the 
neonatal intensive care unit due to prematurity at 26 weeks of gestation 
to a 26-year-old G1 P0 mother whose pregnancy was complicated by 
prolonged premature rupture of membranes, preterm labor, recurrent 
urinary tract infections and renal calculi. Family history was otherwise 
unremarkable. Prenatal ultrasound at 25 weeks of gestation was re-
ported as normal. Her birth weight was 1000 g (90th percentile); birth 
length was 36.5 cm (94th percentile) and head circumference was 23 cm 
(44th percentile). APGAR scores were 6 and 9 at 1 and 5 minutes of life, 
respectively. She was started on continuous positive airway pressure 
(CPAP) due to prematurity and was later transitioned to non-invasive 
positive pressure ventilation (NIPPV) due to desaturations. She was 
begun on a course of ampicillin and gentamicin due to prolonged 
rupture of membranes. Her physical examination was unremarkable 
without coarse facial features; however, a chest radiograph revealed 
generalized diffuse severe bone demineralization and multiple fractures, 
which raised concern for hyperparathyroidism. Further evaluation 
revealed mildly elevated ionized calcium (5.26 mg/dL, normal range 
3.90–5.20 mg/dL), an elevated parathyroid hormone (PTH) level (471 
pg/mL, normal range 14–72 pg/mL), mildly low 25-hydroxyvitamin D 
(17 ng/mL, normal range 20–100 ng/mL), elevated magnesium (3.2 
mg/dL, normal range 1.4–2.5 mg/dL), normal phosphorus (4.5 mg/dL, 
normal range 4.0–9.0 mg/dL) and elevated alkaline phosphatase (832 
units/L, normal range 110–320 mg/dL). Maternal calcium, magnesium, 
phosphorus, PTH and 25-hydroxyvitamin D were within the normal 
range. PTH in subsequent studies of the proband showed improvement 
to suggest secondary hyperparathyroidism. Vitamin D was initiated with 
subsequent decrease in PTH level and normalization occurred at 8 weeks 
of age; however, alkaline phosphatase has remained elevated. She 
developed significant abdominal distention which improved with 
decrease feeding volume. Oral feeds were intiated at 14 weeks of life; 
however she struggled to achieve caloric goal. Gastrostomy tube was 
placed prior to discharge. In terms of respiratory support, she was later 
transitioned from NIPPV to nasal cannula; however, she developed 
desaturation on room air. She was then discharged at 16 weeks of life 
with low-flow nasal cannula. She failed auditory brainstem response 
(ABR) test. Repeat audiologic study revealed mild-to-moderate bilateral 
conductive hearing loss. 
2.2. Molecular and biochemical analysis 
Genetic testing for GNPTAB was performed on the index patient and 
her parents by Prevention Genetics (Marshfield, WI). Genomic DNA was 
extracted from buccal swabs of the proband as well as the parents. DNA 
corresponding to these regions was captured using an optimized set of 
DNA hybridization probes. Captured DNA was sequenced using Illumi-
na’s Reversible Dye Terminator (RDT) platform (Illumina, San Diego, 
CA, USA). Regions with insufficient coverage by next-generation 
sequencing (NGS) were covered by Sanger sequencing. Copy number 
variants (CNVs) were detected from NGS data utilizing a CNV calling 
algorithm that compares mean read depth and distribution for each 
target in the test sample against multiple matched controls. The depth of 
coverage was more than 20× for all coding exons of GNPTAB, GNPTC 
and NAPGA, plus approximately 10 bases flanking of noncoding DNA. 
Lysosomal enzyme testing was performed by Lysosomal Diseases 
Testing Laboratory, Thomas Jefferson University (Philadelphia, PA) 
[20]. Urine mucopolysaccharidosis analysis and urinary oligosaccharide 
analysis were performed by Greenwood Genetic Center (Greenwood, 
SC) using mass spectrometry based methods [21–23]. Total glycosami-
noglycans were measured using dye binding methods. 
2.3. Gross and microscopic examination of the placenta 
Gross examination with prosection of the placenta was performed by 
standard surgical pathology techniques. The weight of the placental disc 
with trimmed fetal membranes was measured and compared to a stan-
dard reference range of placental weights for reported fetal gestational 
age at birth. Placental sections submitted for microscopic examination 
were formalin fixed/paraffin embedded and cut slides were hematoxylin 
and eosin stained using standard histology techniques and were exam-
ined by light microscopy. An additional section of placenta was fixed in 
glutaraldehyde for electron microscopy by standard techniques, per-
formed using standard techniques at the Washington University School 
of Medicine Department of Pathology and Immunology electron mi-
croscopy facility. 
3. Results 
3.1. Placental pathology 
Gross examination showed a 12.5 × 12.0 × 2.7 cm singleton placenta 
with an attached segment of unremarkable trivascular umbilical cord 
inserting paracentrically 4.2 cm from the placental disc margin. 
Attached membranes were opaque with eccentric rupture 2.5 cm from 
the nearest placental disc margin. The fetal surface was pink in color 
with gross sub-amniotic hemorrhage. The maternal surface was dis-
rupted. Trimmed weight of the placenta was 183.6 g which was small for 
pre-term female neonates born at 26 weeks gestational age and corre-
sponding to less than the 10th percentile for gestational age. Sections of 
the placental disc showed no additional gross findings. 
Microscopic examination showed a trivascular umbilical cord and 
fetal membranes showed no histopathologic abnormality. The chorionic 
villi with appropriate maturation for gestational age revealed fine 
vacuolization of syncytiotrophoblasts and stromal expansion by multi-
vacuolated Hofbauer cells (fetal macrophages) (Fig. 1). Extensive cyto-
plasmic vacuolization of Hofbauer cells with some electron dense 
material within the vacuoles was identified ultrastructurally (Fig. 2). 
These vacuoles were most consistent with lysozymes containing lipid 
suggestive of mucolipidoses, namely MLII [17] or mucolipidosis type IV 
[18]. 
3.2. Biochemical and molecular analysis 
Lysosomal enzyme testing in leukocytes was normal; however, 
plasma lysosomal enzymes including β-galactosidase, β-mannosidase, 
α-L-fucosidase, α-mannosidase and α-glucosaminidase activities were 
substantially elevated; this finding is consistent with MLII or MLIIIα/β. 
Targeted sequencing revealed that the patient was homozygous for a 
pathogenic variant in GNPTAB, denoted NM_024312.5: c.3505_3504del 
(p.Leu1168Glnfs*5). This variant has been previously reported to be 
causative for MLII. Both parents were found to be heterozygotes. 
Urine mucopolysaccharides analysis revealed a non-specific pattern 
(Table 1). At 2 days of life, all individual GAGs, including chondroitin 
sulfate (CS), heparan sulfate (HS), dermatan sulfate (DS) and keratan 
sulfates (KS) were elevated, with normal total GAGs. Repeat study at 2 
months of age consistently showed elevation of CS, HS and KS. The total 
GAGs were also elevated, while DS normalized. A similar pattern was 
noted in two additional samples taken at 2 months of age. 
Urinary oligosaccharide analysis demonstrated significant elevations 
(3.6–11.3 times) of a sialylated oligosaccharide marker 
P. Wongkittichote et al.                                                                                                                                                                                                                        
Molecular Genetics and Metabolism Reports 27 (2021) 100747
3
(Neu5Ac1Hex3HexNAc2) in all four urine samples. Other markers 
(Hex1HexNAc1, Hex3HexNAc1, Hex3HexNAc2) were elevated in most 
samples but to a lesser degree (1–3.3 times). 
4. Discussion 
The placental examination provides the opportunity to identify both 
maternal and fetal findings which correlate a variety of pregnancy 
associated complications from maternal vascular malperfusion with in-
trauterine growth restriction to fetal infections of various types in the 
presence of fetal hydrops. Our case illustrates that clinically pertinent 
findings (and subsequent diagnoses made) are by no means restricted to 
these narrow diagnostic categories and can include a number of 
biochemical disorders – namely inborn errors of lipid metabolism. It has 
been appreciated for some time that electron microscopy is especially 
useful in a variety of inherited lipid storage disorders with the lysosomal 
accumulation of metabolic material in Hofbauer cells as it does else-
where in fetal macrophages in the liver, spleen and lymph nodes [24]. 
Here we present a case where the findings of placental lipidosis raised 
concern for an inborn error of lipid metabolism, which was further 
confirmed by electron microscopic studies showing lysosomal lipid in-
clusions as well as biochemical and genetic evidence of MLII. While MLII 
is a rare genetic disease, even rarer are reports in the literature of di-
agnoses being made based on placental findings [17,18,25]. 
A diagnosis of MLII is usually suspected based on clinical charac-
teristics include early signs of dysmorphic features and abnormal skel-
etal findings which may be present at birth to early infancy [10]. 
However, our case demonstrated that coarse facial features can be mild 
or even absent in preterm newborns with MLII, but may develop later. 
Skeletal findings, in combination with abnormal placental pathology, 
can lead to the early recognition of MLII. 
Spontaneous abortion and stillbirth have been reported among cases 
with MLII [26,27]. In a cohort of individuals diagnosed with MLII, 
Cathey SS et al. reported that two out of 14 had preterm deliveries [10]. 
Aborted fetuses were found to have abnormal placental pathology with 
extensive cytoplasmic vacuolization of chorionic villi [27]. MLII might 
increase the risk of stillbirth and preterm labor, partially due to 
Fig. 1. Hematoxylin and Eosin section showing trophoblastic lipidosis. Foamy 
vacuolization surrounding the periphery of the villus was noted, corresponding 
to lysosomal lipid inclusions. 
Fig. 2. Electron micrograph of placental villus. Trophoblastic lipidosis was 
shown, consistent with lysosomal lipid inclusions. 
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placental injury from accumulation of storage material. 
Our patient also had transient secondary hyperparathyroidism, 
which has been previously reported in association with MLII [28–31]. 
The initially elevated PTH later normalized; however, alkaline phos-
phatase has remained elevated, similar to previously reported examples 
[29,30]. The cause of this endocrine abnormality is currently unclear. 
Sathasivam, et al, proposed that abnormal placental structure and 
function may lead to impaired placental calcium transport and subse-
quent secondary hyperparathyroidism and ricket-like bone changes 
[31]. Alternatively, David-Vizcarra, et al, hypothesized that GlcNAc-1- 
phosphotransferase deficiency causes defective targeting of one of the 
components of PTH signal transduction, leading to tissue PTH hyper-
sensitivity and PTH hypersecretion from disrupted biofeedback [30]. 
Abnormal elevation of GAGs has been reported in the settings of MLII 
and MLIIIα/β patients [31]. One patient was reported to have elevation 
of DS, HS and KS, while another patient was found to have only DS 
elevation. Our patient showed elevated total and individual GAGs. This 
pattern differs from previous studies with the elevation of CS, HS, and 
KS. Additionally, abnormal urinary oligosaccharides have been reported 
in MLII and MLIIIα/β patients [21]. Our patient showed persistent ele-
vations of a sialylated oligosaccharide and to a lesser degree other non- 
sialyated oligosaccharides. The abnormal levels of GAGs and oligosac-
charides in mucolipidoses are less significant than those in mucopoly-
saccharidoses and glycoproteinoses, respectively; however, in 
conjunction with other clinical features, mild nonspecific elevation of 
both tests can support a diagnosis of MLII. Additionally our data show 
these mild elevations persist over multiple samples and are present in 
the first week of life. 
We have described a premature infant who was diagnosed with MLII 
on the basis of placental lipidosis, skeletal findings and subsequent ge-
netic confirmation. To our knowledge, this patient is the most premature 
patient with MLII to date that has been reported. Given the absence of 
classical craniofacial features at the time of diagnosis, this report has 
highlighted the importance of placental pathological examination in 
cases of unsuspected disorders especially of an inherited metabolic 
nature. 
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